|
|
Volumn 23 Suppl 1, Issue , 2005, Pages 49-61
|
|
Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BENZODIAZEPINE DERIVATIVE;
HALOPERIDOL;
NEUROLEPTIC AGENT;
OLANZAPINE;
RISPERIDONE;
ARTICLE;
COST BENEFIT ANALYSIS;
COST OF ILLNESS;
DELAYED RELEASE FORMULATION;
ECONOMICS;
GERMANY;
HUMAN;
ORAL DRUG ADMINISTRATION;
PHARMACOECONOMICS;
QUALITY ADJUSTED LIFE YEAR;
SCHIZOPHRENIA;
STATISTICAL MODEL;
ADMINISTRATION, ORAL;
ANTIPSYCHOTIC AGENTS;
BENZODIAZEPINES;
COST OF ILLNESS;
COST-BENEFIT ANALYSIS;
DELAYED-ACTION PREPARATIONS;
ECONOMICS, PHARMACEUTICAL;
GERMANY;
HALOPERIDOL;
HUMANS;
MODELS, ECONOMIC;
QUALITY-ADJUSTED LIFE YEARS;
RISPERIDONE;
SCHIZOPHRENIA;
|
|
EID: 33644831302
PISSN: 11707690
EISSN: None
Source Type: Journal
DOI: 10.2165/00019053-200523001-00005 Document Type: Article |
|
Times cited : (53)
|
|
References (0)
|
